BridgeBio Pharma Inc. (NASDAQ:BBIO) went down by -15.52% from its latest closing price compared to the recent 1-year high of $65.33. The company’s stock price has collected -32.78% of loss in the last five trading sessions. Barron’s reported on 12/28/21 that BridgeBio Rallies After Its Worst Trading Day. Stocktwits Mentions Are Rising.
Is It Worth Investing in BridgeBio Pharma Inc. (NASDAQ :BBIO) Right Now?
Opinions of the stock are interesting as 9 analysts out of 10 who provided ratings for BridgeBio Pharma Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $25.00, which is $19.9 above the current price. BBIO currently public float of 98.47M and currently shorts hold a 19.20% ratio of that float. Today, the average trading volume of BBIO was 2.50M shares.
BBIO’s Market Performance
BBIO stocks went down by -32.78% for the week, with a monthly drop of -50.78% and a quarterly performance of -44.83%, while its annual performance rate touched -87.82%. The volatility ratio for the week stands at 13.00% while the volatility levels for the past 30 days are set at 9.52% for BridgeBio Pharma Inc.. The simple moving average for the period of the last 20 days is -40.80% for BBIO stocks with a simple moving average of -81.43% for the last 200 days.
Analysts’ Opinion of BBIO
Many brokerage firms have already submitted their reports for BBIO stocks, with SVB Leerink repeating the rating for BBIO by listing it as a “Outperform.” The predicted price for BBIO in the upcoming period, according to SVB Leerink is $24 based on the research report published on December 27th of the previous year 2021.
Mizuho, on the other hand, stated in their research note that they expect to see BBIO reach a price target of $25, previously predicting the price at $86. The rating they have provided for BBIO stocks is “Buy” according to the report published on December 27th, 2021.
BofA Securities gave a rating of “Buy” to BBIO, setting the target price at $75 in the report published on September 10th of the previous year.
BBIO Trading at -41.26% from the 50-Day Moving Average
After a stumble in the market that brought BBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.34% of loss for the given period.
Volatility was left at 9.52%, however, over the last 30 days, the volatility rate increased by 13.00%, as shares sank -48.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.35% lower at present.
During the last 5 trading sessions, BBIO fell by -32.78%, which changed the moving average for the period of 200-days by -71.98% in comparison to the 20-day moving average, which settled at $9.30. In addition, BridgeBio Pharma Inc. saw -66.07% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at BBIO starting from Ellis Andrea, who purchase 12,000 shares at the price of $8.39 back on Mar 15. After this action, Ellis Andrea now owns 12,000 shares of BridgeBio Pharma Inc., valued at $100,680 using the latest closing price.
Dachille Douglas A., the Director of BridgeBio Pharma Inc., purchase 10,000 shares at $8.19 during a trade that took place back on Mar 14, which means that Dachille Douglas A. is holding 20,000 shares at $81,934 based on the most recent closing price.
Stock Fundamentals for BBIO
Current profitability levels for the company are sitting at:
- -827.12 for the present operating margin
- +90.88 for the gross margin
The net margin for BridgeBio Pharma Inc. stands at -806.90.
The liquidity ratio also appears to be rather interesting for investors as it stands at 6.58.